Development and evaluation of a novel DNA vaccine expressing inhibin α (1–32) fragment for improving the fertility in rats and sheep

Han, Li; Mao, Dagan; Zhang, D.K.; Liang, Aixin; Fang, Ming; Moaeen‐ud‐Din, Muhammad; Yang, Liguo

doi:10.1016/j.anireprosci.2007.12.012

Cited by 30 publications

(30 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study showed that HBsAg could enhance the immunogenicity of inhibin, which is a weak antigen as well (Han et al, 2007). In the present study, the HBsAg was used to enhance the DNA vaccine of SS.…”

Section: Discussionmentioning

confidence: 78%

“…The reaction was stopped by the addition of 0.2 M H 2 SO 4 and the resulting optical density (OD) at 450 was analyzed with a plate reader (Thermo Electron Corporation). The results were judged by the P/N value, where P is the optical density of the detected sample and N is the optical density of the negative control sample (Han et al, 2007). If the P/N value was more than 2, it was regarded as positive, otherwise as negative.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the VP22 gene adjuvant for enhancement of DNA vaccine against somatostatin in mice

Han

Liang

Zhang

et al. 2008

Animal

Self Cite

View full text Add to dashboard Cite

Somatostatin (SS) is a hormone that inhibits the secretion of growth hormone. Immunization against SS can promote the growth of animals. A novel SS-VP22 fused vaccine, pEGS2SS-V, was constructed from pEGS2SS plasmid with a VP22 gene fragment. Two times of immunization with pEGS2SS-V-induced anti-SS antibodies in mice. Compared with mice immunized with pEGS2SS and 0.85% saline, the growth performance of mice immunized with pEGS2SS-V was increased by 14.1% (P , 0.05) and 48.4% (P , 0.01) on the 2nd week after the first vaccination, respectively. The results indicated that the effects of the somatostatin DNA vaccine could be improved effectively by VP22 gene adjuvant.Keywords: BHV-1 VP22, somatostatin, DNA vaccine IntroductionThe circadian and pulsatile secretion of growth hormone (GH) from the anterior pituitary gland plays a crucial role in postnatal longitudinal growth and development, tissue growth, lactation, reproduction, as well as protein, lipid and carbohydrate metabolism (Ohlsson et al., 1998;Ayuk and Sheppard, 2006). The secretion of GH is down-regulated by somatostatin (SS), which is secreted by the hypothalamus (Vance et al., 1992). The SS has broad inhibitory effect on animals, especially on animal growth and immune response; thus, exhausting or immuno-neutralizing the SS level could lead to increase in GH and promote animal growth (Ohlsson et al., 1998). Therefore, as an alternative approach to direct GH injection, immunization against SS that inhibits GH secretion has been suggested as a method to promote the growth of animals by inactivating SS in the plasma.SS is a 14-peptide-hormone with a small molecular weight and a very short half-life. Synthetic SS conjugated to a carrier protein promotes the growth rates of immunized animals, including lambs, steers and chickens (Buonomo et al., 1987;Van Kessel et al., 1990). However, native SS preparation is limited in source.Chemical synthesis is inefficient for polypeptides longer than about 300 amino acids, and the synthesized proteins may not readily assume their native tertiary structure. Besides, these programs are time-consuming and relatively expensive, which limit the application of SS immunization to promote animal growth.DNA immunization represents a novel vaccine strategy (Tang et al., 1992). So far, there have been several reports on DNA vaccines encoding the SS gene that can promote the growth of immunized animals in our lab (Liang et al., 2008). However, the potency of naked DNA vaccines is limited by their inability to amplify and spread in vivo; in primates and other large animals the responses are less impressive and the quantities of DNA required may be large (Calarota et al., 1998;Macgregor et al., 1998;Wang et al., 1998). It was reported that the tegument protein VP22 of bovine herpesvirus-1 (BHV-1) could increase the immunogenicity of antigens to which it was fused (Oliveira et al., 2001;Wills et al., 2001;Hung et al., 2002). VP22 of BHV-1 is a 258 amino acid tegument protein (Liang et al., 1995) that can transport proteins to neighbor...

show abstract

Section: Discussionmentioning

confidence: 78%

mentioning

confidence: 99%

Evaluation of the VP22 gene adjuvant for enhancement of DNA vaccine against somatostatin in mice

Han

Liang

Zhang

et al. 2008

Animal

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, as they have mainly been applied against various pathogens and tumor antigens (Kutzler and Weiner, 2008), there are only a few reports that have tested their immunity against endogenous antigens of reproduction performance in animals (Han et al, 2008;Wang et al, 2012). As described above, there are some limitations to the recombinant plasmid method, leading to efforts focused on developing novel vaccine vectors such as attenuated Salmonella.…”

Section: A B C Discussionmentioning

confidence: 99%

“…The preparation and purification of a conventional vaccine is timeconsuming and labor-intensive. Because of their convenience, stability, and cost, a variety of DNA vaccines encoding the inhibin α (1-32) gene or a fusion with the S gene of the hepatitis B surface antigen have been developed (Han et al, 2008;Wang et al, 2012), and the results showed that an inhibin DNA vaccine was a promising tool for improving animal fertility. However, DNA vaccines face several problems such as low-uptake efficiency (Greenland et al, 2007), dose-dependence (Huang et al, 2008), low immunogenicity in humans and large animals (Melkebeek et al, 2007), and, particularly, antibiotic-resistance-based plasmid selection systems (Galen et al, 2010), making it important to develop an alternative approach for inhibin DNA vaccination.…”

Section: Introductionmentioning

confidence: 99%

“…This system involved the use of an artificial mutant of an S. choleraesuis C500 strain capable of double deletion of the cyclic AMP receptor protein (crp) and β-aspartic semialdehyde dehydrogenase (asd) genes, and an inhibin recombinant plasmid, pVAX-IS-asd (pXAIS), without antibiotic resistance based on a previous study (Han et al, 2008;Zhen et al, 2009). The objectives of this study were to determine the safe dosage of the S. choleraesuismediated vaccine and to assess the effect of this vaccine on the serum antibody titer against inhibin and follicular development in rats.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of attenuated Salmonella choleraesuis-mediated inhibin recombinant DNA vaccine in rats

Hui¹,

Meng²,

Guo³

et al. 2014

Genet. Mol. Res.

Self Cite

View full text Add to dashboard Cite

ABSTRACT. DNA vaccination has been studied intensively as a potential vaccine technology. We evaluated the effect of an attenuated Salmonella choleraesuis-mediated inhibin DNA vaccine in rats. First, 15 rats were treated with different doses of an inhibin vaccine to evaluate vaccine safety. Next, 30 rats were divided into 3 groups and injected intramuscularly with the inhibin vaccine two (T1) or three times (T2) or with control bacteria (Con) at 4-week intervals. The inhibin antibody levels increased [positive/negative well (P/N) value: T1 vs Con = 2.39 ± 0.01 vs 1.08 ± 0.1; T2 vs Con = 2.36 ± 0.1 vs 1.08 ± 0.1, P < 0.05] at week 2 and were maintained at a high level in T1 and T2 until week 8, although a small decrease in T2 was observed at week 10. Rats in the T1 group showed more corpora lutea compared with the Con group (10.50 ± 0.87 vs 7.4 ± 0.51, P < 0.05). Estradiol (0.439 ± 0.052 vs 0.719 ± 0.063 ng/mL, P < 0.05) and progesterone (1.315 ± 0.2 vs 0.737 ± 0.11 ng/mL, P < 0.05) levels differed significantly at metestrus after week 10 between rats in the T1 and Con groups. However, there were no significant differences in body, ovary, uterus weights, or pathological signs in the ovaries after immunization, indicating that this vaccine is safe. In conclusion, the attenuated S. choleraesuis-mediated inhibin vaccine may be an alternative to naked inhibin plasmids for stimulating ovarian follicular development to increase the ovulation rate in rats.

show abstract

Oral vaccination with inhibin DNA delivered using attenuated Salmonella choleraesuis for improving reproductive traits in mice

Han

Zhen

Liang

et al. 2013

J. Basic Microbiol.

Self Cite

View full text Add to dashboard Cite

The objective of this study was to examine the efficacy and safety of a novel inhibin vaccine containing inhibin α (1–32) fragments in mice. A recombinant plasmid pVAX‐asd‐IS was constructed by inserting recombinant inhibin α (1–32) and the hepatitis B surface antigen S into the plasmid in which the asd gene, rather than the kanamycin gene, was a selection marker. Ninety Kuming mice were divided into six groups consisting of 15 mice each. First group was (C1) injected with 200 µl of PBS, second (C2) received 1 × 1010 CFU of crp−/asd− C500/pVAX‐asd and served as vector control, third did not receive any treatment (C3), while fourth, fifth, and sixth group received 1 × 1010, 1 × 109, 1 × 108 CFU of the recombinant inhibin vaccine crp−/asd− C500/pVAX‐asd‐IS (group T1, T2, T3), respectively. Western blotting demonstrated that recombinant expressed inhibin protein possessed immune function and that this plasmid could replicate for up to 40 generations stably. Vaccination with this strain at a dose of 1 × 1010 CFU/200 µl per mouse induced high anti‐inhibin antibody levels, significantly increased large‐follicle production in T1 group (p < 0.05) and average litter size (p > 0.05) compared with control groups. Integration studies showed no evidence of inhibin fusion gene integrated into mice's genome 2‐month after immunization. These results suggest that the vaccine described in the present study may provide a safe method to improve reproductive traits in animals. A trend towards increased litter size and significant increase in large follicle population depict that this vaccine may have direct application in large animal industry.

show abstract

Development and evaluation of a novel DNA vaccine expressing inhibin α (1–32) fragment for improving the fertility in rats and sheep

Cited by 30 publications

References 41 publications

Evaluation of the VP22 gene adjuvant for enhancement of DNA vaccine against somatostatin in mice

Evaluation of the VP22 gene adjuvant for enhancement of DNA vaccine against somatostatin in mice

Evaluation of attenuated Salmonella choleraesuis-mediated inhibin recombinant DNA vaccine in rats

Oral vaccination with inhibin DNA delivered using attenuated Salmonella choleraesuis for improving reproductive traits in mice

Contact Info

Product

Resources

About